Results from a Human Factor Study Supporting Safe and Effective Use of the Lecanemab Subcutaneous Autoinjector

Abstract

Background: Lecanemab is a novel, humanized immunoglobulin G (IgG) 1 monoclonal antibody, which has demonstrated the ability to substantially reduce markers of amyloid and slow clinical decline in early Alzheimer’s disease (AD).

The paper